# PLAT-02 (NCT02028455)

> A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia

No report yet. It can be ordered.

- Drugs tested: none (the trial tests no drug)
- Indication: pediatric and young adult relapsed/refractory CD19+ acute leukemia

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02028455
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Seattle Children's Hospital
- Conditions: CD19+ Acute Leukemia
- Interventions: Patient Derived CD19 specific CAR T cells also expressing an EGFRt
- Enrollment: 167
- Primary outcome: Number of Participants Who Experienced an Adverse Event Meeting the Dose-Limiting Toxicity Definition
- Primary outcome: Number of Participants With an MRD Negative Complete Remission After Initial CAR T Cell Infusion
- Primary outcome: Number of Participants Who Have a Releasable Cell Product Generated

## Indexed commentary on PLAT-02 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 1
- Podcasts: 1
- X threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=plat-02-nct02028455